Wolverine Trading’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $371K | Buy |
+17,400
| New | +$412K | ﹤0.01% | 4066 |
|
|
2025
Q2 | – | Sell |
-29,900
| Closed | -$510K | – | 4535 |
|
|
2025
Q1 | $510K | Buy |
29,900
+15,400
| +106% | +$280K | ﹤0.01% | 2949 |
|
|
2024
Q4 | $242K | Sell |
14,500
-1,200
| -8% | -$19.4K | ﹤0.01% | 4280 |
|
|
2024
Q3 | $246K | Buy |
+15,700
| New | +$262K | ﹤0.01% | 3836 |
|
|
2024
Q2 | – | Sell |
-19,500
| Closed | -$361K | – | 4374 |
|
|
2024
Q1 | $361K | Buy |
+19,500
| New | +$483K | ﹤0.01% | 3168 |
|
|
2023
Q4 | – | Sell |
-18,700
| Closed | -$390K | – | 4420 |
|
|
2023
Q3 | $390K | Buy |
+18,700
| New | +$508K | ﹤0.01% | 3015 |
|
|
2023
Q1 | – | Sell |
-24,900
| Closed | -$396K | – | 4123 |
|
|
2022
Q4 | $396K | Buy |
24,900
+3,500
| +16% | +$54.7K | ﹤0.01% | 2533 |
|
|
2022
Q3 | $345K | Buy |
+21,400
| New | +$347K | ﹤0.01% | 3006 |
|
|
2021
Q4 | – | Sell |
-12,300
| Closed | -$209K | – | 5574 |
|
|
2021
Q3 | $209K | Buy |
+12,300
| New | +$237K | ﹤0.01% | 5269 |
|
|
2021
Q2 | – | Sell |
-49,800
| Closed | -$1.28M | – | 5723 |
|
|
2021
Q1 | $1.28M | Buy |
+49,800
| New | +$2.19M | ﹤0.01% | 2435 |
|
|
2020
Q4 | – | Sell |
-30,300
| Closed | -$1.22M | – | 4718 |
|
|
2020
Q3 | $1.22M | Buy |
30,300
+8,300
| +38% | +$358K | ﹤0.01% | 1878 |
|
|
2020
Q2 | $1.06M | Buy |
+22,000
| New | +$1.06M | ﹤0.01% | 1945 |
|
|
2020
Q1 | – | Sell |
-50,800
| Closed | -$2.19M | – | 4520 |
|
|
2019
Q4 | $2.19M | Buy |
+50,800
| New | +$2.21M | 0.01% | 1756 |
|
|
2019
Q2 | – | Sell |
-37,500
| Closed | -$1.01M | – | 4329 |
|
|
2019
Q1 | $1.01M | Sell |
37,500
-23,000
| -38% | -$537K | ﹤0.01% | 2059 |
|
|
2018
Q4 | $947K | Sell |
60,500
-15,400
| -20% | -$299K | ﹤0.01% | 2011 |
|
|
2018
Q3 | $1.58M | Buy |
+75,900
| New | +$1.19M | ﹤0.01% | 1897 |
|
|
2017
Q4 | – | Sell |
-29,500
| Closed | -$1.11M | – | 4718 |
|
|
2017
Q3 | $1.11M | Buy |
29,500
+3,400
| +13% | +$111K | ﹤0.01% | 1817 |
|
|
2017
Q2 | $749K | Sell |
26,100
-14,800
| -36% | -$441K | ﹤0.01% | 2029 |
|
|
2017
Q1 | $1.4M | Sell |
40,900
-103,000
| -72% | -$3.64M | 0.01% | 1446 |
|
|
2016
Q4 | $4.15M | Buy |
143,900
+23,600
| +20% | +$624K | 0.02% | 845 |
|
|
2016
Q3 | $3.93M | Buy |
+120,300
| New | +$4.08M | 0.02% | 885 |
|
Other funds holding ACAD
BBA
RI
PAI
B
Wolverine Trading's ACAD Position: Q4 2023 in Review
Wolverine Trading sold out of Acadia Pharmaceuticals (ACAD) in Q4 2023, closing a stake of 15,149 shares — an estimated $316K sold.
Wolverine Trading first reported a position in ACAD in Q3 2016 and held it in 9 quarters. The position peaked at $1.43M in Q1 2017. 275 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.
- Wolverine Trading reported no remaining Acadia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
- Wolverine Trading sold 15,149 Acadia Pharmaceuticals shares in Q4 2023, an estimated $316K.
- Wolverine Trading first reported a position in Acadia Pharmaceuticals in Q3 2016 and held it in 9 quarters.
- Wolverine Trading's Acadia Pharmaceuticals position peaked at $1.43M in Q1 2017.
- 275 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.
Based on Wolverine Trading's 13F filing for Q4 2023, filed 14 Feb 2024.